We have located links that may give you full text access.
Acetylcholine receptor antibodies in patients with Graves' ophthalmopathy.
Journal of Neuro-ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society 1995 September
OBJECTIVES: To determine the frequency and clinical correlates of acetylcholine receptor (AChR) antibody seropositivity in patients with Graves' ophthalmopathy.
MATERIALS AND METHODS: Fifty consecutive new patients with Graves' ophthalmopathy diagnosed in an outpatient neuro-ophthalmology practice underwent determination of AChR-binding antibodies. Clinical and biochemical thyroid variables were compared between seropositive and seronegative patients. Clinical variables included age, sex, thyroid disorder, and duration and course of illness. Biochemical variables included thyroid hormone levels and thyroid antibodies. Seropositive patients were followed clinically to identify signs of myasthenia gravis.
RESULTS: Four of 50 (8%) patients had definitely elevated levels of AChR-binding antibodies. No obvious differences existed between the seropositive and seronegative groups in regards to age, sex, underlying thyroid disorder, biochemical thyroid state, presence of thyroid antibodies, or duration and course of their disease. None of the four seropositive patients developed signs of myasthenia gravis during the median follow-up period of 4.5 years.
CONCLUSION: AChR-binding antibody seropositivity occurs in a small proportion of patients with Graves' ophthalmopathy but, by itself, does not necessarily identify an individual with concurrent myasthenia gravis or an individual at risk to develop myasthenia gravis.
MATERIALS AND METHODS: Fifty consecutive new patients with Graves' ophthalmopathy diagnosed in an outpatient neuro-ophthalmology practice underwent determination of AChR-binding antibodies. Clinical and biochemical thyroid variables were compared between seropositive and seronegative patients. Clinical variables included age, sex, thyroid disorder, and duration and course of illness. Biochemical variables included thyroid hormone levels and thyroid antibodies. Seropositive patients were followed clinically to identify signs of myasthenia gravis.
RESULTS: Four of 50 (8%) patients had definitely elevated levels of AChR-binding antibodies. No obvious differences existed between the seropositive and seronegative groups in regards to age, sex, underlying thyroid disorder, biochemical thyroid state, presence of thyroid antibodies, or duration and course of their disease. None of the four seropositive patients developed signs of myasthenia gravis during the median follow-up period of 4.5 years.
CONCLUSION: AChR-binding antibody seropositivity occurs in a small proportion of patients with Graves' ophthalmopathy but, by itself, does not necessarily identify an individual with concurrent myasthenia gravis or an individual at risk to develop myasthenia gravis.
Full text links
Related Resources
Trending Papers
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology 2024 April 17
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.Mayo Clinic Proceedings 2024 April
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app